Inactive Instrument

Analyst Reco. Oxis International OTC Bulletin Board

Equities

EF Hutton Starts GT Biopharma at Hold With $2 Price Target	05/23/05	MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	13/22/13	MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	12/22/12	MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	24/22/24	MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	24/21/24	MT
GT BIOPHARMA : HC Wainwright Starts GT Biopharma at Buy With $25 Price Target	24/21/24	MT
GT BIOPHARMA : B. Riley Starts GT Biopharma at Buy with $21 PT, Says Solid Tumor Indications Represent Source of Potential Upside	13/21/13	MT
GT BIOPHARMA : Roth Capital Starts GT Biopharma at Buy With $25 Price Target	17/21/17	MT

No results for this search